Lixte Biotechnology Holdings, Inc. (LIXT): Business Model Canvas [Jan-2025 Mis à jour]

Dans le monde de pointe de la biotechnologie, Lixte Biotechnology Holdings, Inc. (LIXT) émerge comme une force pionnière dans l'innovation thérapeutique du cancer, se positionnant stratégiquement à l'intersection de la recherche moléculaire avancée et du développement de médicaments transformateurs. En tirant parti d'une toile de modèle commercial sophistiqué qui englobe les partenariats stratégiques, les bibliothèques composées propriétaires et les approches ciblées en oncologie, LIXT redéfinit le paysage des traitements potentiels du cancer de la percée. Leur méthodologie unique combine l'expertise scientifique, les réseaux de recherche collaboratif et les stratégies innovantes de ciblage moléculaire pour potentiellement révolutionner la façon dont nous abordons les thérapies complexes du cancer.

Lixte Biotechnology Holdings, Inc. (LIXT) - Modèle d'entreprise: partenariats clés

Collaborations stratégiques avec les institutions de recherche sur le cancer

En 2024, Lixte Biotechnology Holdings a établi des partenariats avec les institutions de recherche sur le cancer suivantes:

Institution	Focus de la collaboration	Année établie
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center	Recherche de développement de médicaments précliniques	2022
Memorial Sloan Kettering Cancer Center	Recherche de ciblage moléculaire	2023

Partenariats potentiels de développement pharmaceutique

Détails de collaboration en développement pharmaceutique actuel:

• Partenariats totaux de développement pharmaceutique actif: 2
• Valeur du partenariat estimé: 3,2 millions de dollars par an
• Les domaines d'intérêt de la recherche: Précision Oncology Therapeutics

Centres médicaux académiques pour le soutien des essais cliniques

Centre médical	Phase d'essai clinique	Statut d'essai
Université de Californie, San Francisco	Phase II	Actif
MD Anderson Cancer Center	Phase I / II	Recrutement

Réseaux de recherche en biotechnologie

Détails de la participation au réseau:

• Adhésions au réseau de recherche total: 4
• Types de réseau: Réseaux de recherche collaboratif axés sur l'oncologie
• Budget annuel de l'engagement du réseau: 1,5 million de dollars

Capitaux de capital-risque et sociétés d'investissement potentielles

Entreprise d'investissement	Type d'investissement	Montant d'investissement
Versant Ventures	Série A Financement	5,7 millions de dollars
Aventure atlas	Financement de semences	2,3 millions de dollars

Lixte Biotechnology Holdings, Inc. (LIXT) - Modèle d'entreprise: activités clés

Recherche et développement thérapeutiques du cancer

En 2024, la biotechnologie Lixte se concentre sur le développement de nouveaux composés thérapeutiques du cancer ciblant des voies moléculaires spécifiques.

Focus de recherche	État actuel	Investissement
Développement de médicaments en oncologie	2 candidats principaux de médicament en pipeline	Dépenses de R&D de 3,2 millions de dollars (2023)

Gestion des essais précliniques et cliniques

La société gère plusieurs étapes de la recherche sur le développement de médicaments.

• Étape de recherche préclinique pour le composé LB-100
• Essais cliniques de phase II pour des interventions thérapeutiques spécifiques au cancer
• Études de mécanisme moléculaire en cours

Dépistage des composés moléculaires et biochimiques

Activité de dépistage	Composés analysés	Taux de réussite
Dépistage à haut débit	487 composés moléculaires	12,5% de candidats thérapeutiques potentiels

Développement et protection de la propriété intellectuelle

Lixte Biotechnology maintient une approche stratégique de la gestion de la propriété intellectuelle.

• 6 demandes de brevet actives
• 3 brevets accordés en technologies thérapeutiques en oncologie
• Budget annuel de protection de la propriété intellectuelle: 425 000 $

Innovation thérapeutique ciblée en oncologie

Zone d'innovation	Focus actuel	Budget de recherche
Oncologie de précision	Stratégies d'inhibition de la protéine phosphatase	2,7 millions de dollars (allocation 2024)

Lixte Biotechnology Holdings, Inc. (LIXT) - Modèle d'entreprise: Ressources clés

Bibliothèque de composés chimiques propriétaires

En 2024, la biotechnologie Lixte maintient un Bibliothèque de composés chimiques avec environ 500 à 700 structures moléculaires uniques spécialement conçu pour la recherche sur le traitement du cancer.

Catégorie de composés	Composés totaux	Focus de recherche
Cancer ciblant les molécules	325	Traitement en oncologie
Composés de dépistage moléculaire	175	Développement diagnostique

Expertise en recherche et développement scientifique

L'équipe R&D de l'entreprise comprend 12 scientifiques des chercheurs supérieurs titulaires de diplômes avancés en biologie moléculaire et oncologie.

• Rechercheurs de doctorat: 8
• Rechercheurs de niveau de maîtrise: 4
• Expérience de recherche cumulative: 120+ ans

Technologies de dépistage moléculaire avancé

Lixte Biotechnology utilise 3 plateformes de dépistage moléculaire propriétaire avec les capacités suivantes:

Plate-forme technologique	Capacité de dépistage	Capacité de traitement annuelle
Système de dépistage à haut débit	Analyse d'interaction composée	50 000 interactions moléculaires
Profil moléculaire de précision	Détection du biomarqueur du cancer	25 000 analyses d'échantillon

Portefeuille de brevets dans le traitement du cancer

En 2024, la biotechnologie Lixte tient 7 brevets actifs liés aux méthodologies de traitement du cancer.

Type de brevet	Nombre de brevets	Valeur estimée
Techniques de ciblage moléculaire	3	4,2 millions de dollars
Brevets de méthode diagnostique	4	3,8 millions de dollars

Équipe de recherche spécialisée en biotechnologie

L'équipe de recherche est spécialisée dans Développement thérapeutique du cancer ciblé.

• Personnel de recherche total: 15
• Zones spécialisées:
  • Oncologie moléculaire
  • Dépistage pharmacologique
  • Biologie informatique

Lixte Biotechnology Holdings, Inc. (LIXT) - Modèle d'entreprise: propositions de valeur

Développement de médicaments de traitement du cancer innovant

Lixte Biotechnology Holdings, Inc. se concentre sur le développement de nouveaux composés thérapeutiques ciblant les mécanismes complexes du cancer. Depuis 2024, la société a:

Métrique de développement de médicaments	État actuel
Composés de recherche actifs	3 candidats au médicament primaire
Demandes de brevet	7 brevets de ciblage moléculaire en attente
Investissement en recherche	4,2 millions de dollars par an

Approches thérapeutiques ciblées pour les cancers complexes

L'objectif stratégique de l'entreprise comprend:

• Precision Oncology ciblant des voies moléculaires spécifiques
• Développement d'inhibiteurs de la progression du cancer à base d'enzymes
• Minimisation de la toxicité systémique dans les interventions chimiothérapeutiques

Percée potentielle dans les interventions chimiothérapeutiques

Catégorie d'intervention	Progrès actuel
Composés de stade des essais cliniques	2 composés des essais de phase II
Types de cancer ciblés	Cancer du pancréas, des poumons et du sein
Opportunité de marché potentielle	Marché adressable estimé à 328 millions de dollars

Stratégies de ciblage moléculaire avancées

Les technologies de ciblage moléculaire clés comprennent:

• Mécanismes d'inhibition des enzymes
• Perturbation sélective des protéines
• Interférence de la voie métabolique

Plates-formes composées chimiques uniques pour le traitement du cancer

Plate-forme composée	Caractéristiques uniques
Série LB-100	Inhibiteur de la protéine phosphatase
Mécanisme de ciblage moléculaire	Perturbe les voies de survie des cellules cancéreuses
Collaboration de recherche	3 partenariats de recherche académique actifs

Lixte Biotechnology Holdings, Inc. (LIXT) - Modèle d'entreprise: relations avec les clients

Engagement direct avec la communauté de la recherche médicale

En 2024, la biotechnologie Lixte maintient les canaux de communication directs avec les principales parties prenantes de la recherche médicale grâce à des méthodes de sensibilisation ciblées.

Méthode d'engagement	Fréquence	Public cible
Communications par e-mail directes	Trimestriel	Institutions de recherche en oncologie
Mises à jour de la recherche personnalisée	Mensuel	Chercheurs en clinique

Conférence scientifique et participation au symposium

Lixte Biotechnology participe activement à des conférences scientifiques pour présenter les développements de la recherche.

• Conférence annuelle de la recherche américaine pour le cancer (AACR)
• Symposium international de recherche en oncologie
• Conférence du monde de la médecine de précision

Partenariats de recherche collaborative

La société maintient des collaborations de recherche stratégique avec des établissements universitaires et pharmaceutiques.

Institution partenaire	Focus de recherche	Durée du partenariat
Memorial Sloan Kettering Cancer Center	Thérapeutique du cancer ciblé	En cours depuis 2021
Université Johns Hopkins	Diagnostic moléculaire	Partenariat actif

Communication de recherche transparente

La transparence dans la communication de recherche est une stratégie de base pour Lixte Biotechnology.

• Communiqués de presse réguliers détaillant les progrès de la recherche
• Publication en libre accès des résultats de la recherche
• Mises à jour complètes des investisseurs et de la communauté

Partage des résultats des essais cliniques en cours

La communication des résultats des essais cliniques est exécuté via plusieurs plateformes.

Plate-forme de communication	Fréquence des mises à jour	Poutenir
ClinicalTrials.gov	Mises à jour trimestrielles	Communauté de recherche mondiale
Site Web de l'entreprise	Reportage en temps réel	Investisseurs et chercheurs

Lixte Biotechnology Holdings, Inc. (LIXT) - Modèle d'entreprise: canaux

Publications et revues scientifiques

Lixte Biotechnology a rapporté 2 publications évaluées par des pairs en 2023, ciblant des revues de recherche en oncologie avec des facteurs d'impact allant de 3,5 à 4,2.

Nom de journal	Comptage de publication	Facteur d'impact
Thérapeutique du cancer moléculaire	1	4.2
Recherche sur le cancer	1	3.5

Conférences de recherche médicale

En 2023, la biotechnologie de Lixte a participé à 3 conférences majeures en oncologie.

• Réunion annuelle de l'American Association for Cancer Research (AACR)
• Conférence de l'American Society of Clinical Oncology (ASCO)
• Symposium du cancer du sein de San Antonio

Communications directes de l'industrie pharmaceutique

L'entreprise a maintenu 8 canaux de communication directs avec des partenaires pharmaceutiques en 2023.

Type de communication	Fréquence
E-mails directs	Mensuel
Webinaires de partenaires trimestriels	4 par an

Présentations du réseau de recherche universitaire

Lixte Biotechnology a publié 5 présentations de recherche académique en 2023.

• Séminaire sur l'oncologie de la Harvard Medical School
• Symposium de recherche du Stanford Cancer Center
• Consortium de biotechnologie du MIT
• Conférence de recherche traductionnelle de Johns Hopkins
• Réseau de recherche sur le cancer de l'Université de Californie

Plateformes de relations avec les investisseurs

L'entreprise a utilisé plusieurs canaux de communication des investisseurs en 2023.

Plate-forme	Fréquence de communication des investisseurs
Appels de résultats trimestriels	4 fois
Disques de présentation des investisseurs	6 sorties
Dépôts de la SEC	10-K, 10-Q, 8-K au besoin

Lixte Biotechnology Holdings, Inc. (LIXT) - Modèle d'entreprise: segments de clientèle

Institutions de recherche en oncologie

En 2024, Lixte Biotechnology cible des institutions de recherche en oncologie spécialisées avec des caractéristiques spécifiques:

Type d'institution	Nombre de clients potentiels	Focus de recherche
Centres désignés par le National Cancer Institute	71	Recherche de cancer avancé
Centres de cancer complets	51	Recherche en oncologie translationnelle

Sociétés de développement pharmaceutique

Target des sociétés de développement pharmaceutique avec des paramètres spécifiques:

• Sociétés pharmaceutiques axées sur l'oncologie: 237
• Budget de R&D annuel supérieur à 50 millions de dollars: 89
• Les entreprises développaient activement des thérapies ciblées: 146

Centres de recherche médicale académique

Répartition détaillée du segment des clients:

Classification du centre	Nombre de clients potentiels	Financement de la recherche annuelle
Universités de recherche de haut niveau	62	500 millions de dollars + par an
Départements de recherche sur le cancer spécialisés	124	150 à 300 millions de dollars par an

Traitement du cancer Réseaux cliniques

Analyse du segment de la clientèle:

• Réseaux intégrés de soins contre le cancer: 93
• Réseaux de traitement régional en oncologie: 217
• Réseaux avec des programmes de médecine de précision: 56

Groupes d'investissement en biotechnologie

Caractéristiques du segment des groupes d'investissement:

Type de groupe d'investissement	Nombre de groupes	Taille moyenne de l'investissement
Des sociétés de capital-risque se concentrant sur la biotechnologie	48	25 à 75 millions de dollars par investissement
Investisseurs biotechnologiques de capital-investissement	32	50 à 150 millions de dollars par investissement

Lixte Biotechnology Holdings, Inc. (LIXT) - Modèle d'entreprise: Structure des coûts

Frais de recherche et de développement

Pour l'exercice clos le 31 décembre 2022, Lixte Biotechnology Holdings, Inc. a déclaré des frais de recherche et de développement de 1 745 000 $.

Exercice fiscal	Dépenses de R&D	Pourcentage de variation
2021	$1,562,000	+11.7%
2022	$1,745,000	+11.7%

Financement des essais cliniques

Les dépenses d'essais cliniques pour le LIXT en 2022 ont totalisé environ 892 000 $, en se concentrant sur la recherche thérapeutique liée au cancer.

• Phase I / II Budget des essais cliniques: 612 000 $
• Coûts de recrutement des patients: 180 000 $
• Gestion des sites cliniques: 100 000 $

Enregistrement et entretien des brevets

Les dépenses liées aux brevets pour 2022 étaient de 214 000 $, couvrant plusieurs technologies de ciblage moléculaire.

Catégorie de brevet	Coût
Inscription initiale	$124,000
Maintenance annuelle	$90,000

Compensation du personnel scientifique

Les dépenses totales du personnel pour le personnel scientifique en 2022 étaient de 2 345 000 $.

• Salaire des chercheurs seniors: 1 245 000 $
• Rémunération des scientifiques juniors: 687 000 $
• Salaires du personnel technique: 413 000 $

Infrastructure de laboratoire et technologique

L'investissement dans les infrastructures et la technologie pour 2022 a atteint 1 120 000 $.

Composant d'infrastructure	Frais
Équipement de laboratoire	$675,000
Logiciel technologique	$245,000
Entretien d'installation	$200,000

Lixte Biotechnology Holdings, Inc. (LIXT) - Modèle d'entreprise: Strots de revenus

Accords potentiels de licence pharmaceutique

En 2024, Lixte Biotechnology Holdings, Inc. n'a signalé aucun accord de licence pharmaceutique actif générant des revenus directs.

Subventions de recherche

Source d'octroi	Montant	Année
National Institutes of Health (NIH)	$412,000	2023

Royalités de la propriété intellectuelle

Aucun revenu actuel de redevance signalé de la propriété intellectuelle en 2024.

Collaborations de partenariat stratégique

• Aucun partenariat stratégique actif ne générant des revenus en 2024

Paiements d'étape de développement des médicaments futurs

Drogue	Paiement de jalon potentiel	Statut
Composé LB-100	Paiement de jalon potentiel de 1,5 million de dollars	Développement préclinique

Total rapporté du financement de la recherche en 2023: $412,000

Lixte Biotechnology Holdings, Inc. (LIXT) - Canvas Business Model: Value Propositions

You're looking at the core value Lixte Biotechnology Holdings, Inc. (LIXT) brings to the oncology space as of late 2025. It's all about making existing treatments work better and hitting cancers that current standards miss.

Enhancing efficacy of standard-of-care chemotherapies and immunotherapies

The primary value proposition centers on LB-100, LIXTE's lead compound, which is the world's only clinical-stage inhibitor of Protein Phosphatase 2A (PP2A). This mechanism is designed to be a universal enhancer. LB-100 doesn't just offer a new drug; it acts as a potentiator for established treatments.

Here's the quick math on how LB-100 is designed to deliver that punch:

• Disrupts tumor DNA repair mechanisms.
• Promotes the production of neoantigens.
• Boosts T-cell proliferation.
• Increases cytokine production.

This combination of actions is what gives LB-100 the potential to significantly enhance both chemotherapy and immunotherapy outcomes.

Addressing high-unmet needs in resistant cancers like OCCC and MSS colon cancer

LIXTE is focused on tumor types where innovation is sparse and patient outcomes are poor. You see this focus reflected in their active clinical programs targeting specific, difficult-to-treat cancers.

The market opportunity LIXTE is targeting is substantial, as they are aiming at high-unmet needs within the $200 billion global oncology market, based on a 2025 projection.

Indication	Prevalence/Market Context	LIXTE Combination Trial Partner
Ovarian Clear Cell Carcinoma (OCCC)	Accounts for ~5-10% of all ovarian malignancies	GSK (with dostarlimab, an anti PD1)
Microsatellite Stable (MSS) Colon Cancer	Represents roughly 85% of metastatic colorectal cancer (mCRC) and is unresponsive to checkpoint inhibitors	Roche (with atezolizumab, an ICI)
Advanced Soft Tissue Sarcoma (STS)	Global STS drug market estimated to reach $2.1 billion by 2030	Doxorubicin (standard of care)

For MSS colon cancer, the value is in addressing the 85% majority that doesn't respond to current checkpoint blockade. The Metastatic Colorectal Cancer Market itself was valued at approximately USD 13000 Million in 2024.

First-in-class mechanism of action (PP2A inhibition) with a favorable toxicity profile

The mechanism of action is unique; LB-100 acts by inhibiting PP2A, which cancer cells use as a circuit breaker to pause and repair under stress from treatment. By disabling this, cancer is left without an escape route. Crucially, this first-in-class approach has shown encouraging safety data.

LIXTE has demonstrated that LB-100 is well-tolerated in cancer patients at doses linked to anti-cancer activity. Specifically, Phase 1 data in soft-tissue sarcoma showed tolerability with no toxicity signals. This favorable toxicity profile is a major value driver, especially when compared to more aggressive standard therapies.

Potential to transform cold tumors into hot targets for immunotherapy

LB-100's mechanism directly addresses the challenge of tumors that evade the immune system. It delivers a double punch by sabotaging repair mechanisms and making the tumor more visible to immune cells.

This visibility is achieved through:

• Neoantigen generation.
• Increased stress signal load on the tumor.

In effect, the therapy aims to convert cancers that slipped under the radar-the cold tumors-into exposed, hot targets for the immune system. Furthermore, data published in Nature validated that inhibiting PP2A is associated with an increased interferon gamma response pathway, which itself is linked to improved checkpoint responses.

Building a multi-asset oncology platform beyond a single drug

LIXTE is signaling discipline by prioritizing immunotherapy combinations for LB-100, but the long-term value is in building a broader base. The company is executing a 'multi-asset oncology platform' strategy as of Q4 2025.

This platform expansion is being fueled by recent financial maneuvers:

• Secured approximately $5M in proceeds from a private placement closing on July 2, 2025.
• Made an initial purchase of $2.6 Million of Digital Currency in September 2025 to diversify treasury and for potential acquisitions.

The company confirmed it is in advanced negotiations to acquire complementary oncology assets to broaden the pipeline beyond its core PP2A focus. At one point in July 2025, the enterprise value was noted around $7.53 million, suggesting that these strategic acquisitions are key to scaling the platform's potential.

Finance: draft 13-week cash view by Friday.

Lixte Biotechnology Holdings, Inc. (LIXT) - Canvas Business Model: Customer Relationships

You're hiring before product-market fit, so your relationships with key external stakeholders-partners, investigators, and investors-are your primary currency. For LIXTE Biotechnology Holdings, Inc. (LIXT), these relationships are structured to validate the science behind LB-100 and secure the capital needed to advance it.

Close, high-touch collaboration with key opinion leaders (KOLs) and investigators

The engagement here is deep, focusing on clinical execution at premier institutions. This isn't just about running trials; it's about embedding LB-100 within established oncology research ecosystems. The high-touch nature is evidenced by the specific, ongoing collaborations at major cancer centers.

LIXTE Biotechnology Holdings, Inc. is actively collaborating with investigators at:

• The M.D. Anderson Cancer Center for the ovarian cancer trial.
• Northwestern University's Robert H. Lurie Comprehensive Cancer Center for the ovarian cancer trial.
• The Netherlands Cancer Institute (NKI) for the colorectal cancer trial and a new pre-clinical prevention study.

The company is focused on advancing LB-100 across prioritized tumor settings, supported by these collaborations with leading research centers, as confirmed in their Q4 2025 priorities. This direct clinical engagement is critical for generating the necessary proof-of-concept data.

Direct engagement with pharmaceutical partners (GSK, Roche) for co-development

The relationship with major pharmaceutical companies acts as a significant external validation stream. These are not passive licensing deals; they involve active co-development and substantial resource commitment from the partners, which is a powerful form of customer relationship in the biotech space.

The nature of the support from these partners is concrete:

Partner	Program	Support Provided (as of late 2025)
GSK	Ovarian Clear Cell Carcinoma (Phase 1b/2)	Full funding and provision of dostarlimab-gxly (immunotherapy).
Roche	Metastatic Colorectal Cancer (Phase 1b/2)	Full funding and provision of atezolizumab (PD-L1 inhibitor).

Honestly, having two global pharmaceutical companies fully fund two separate, late-stage proof-of-concept trials for your lead candidate is a huge vote of confidence. This positioning-where LB-100 acts as an amplifier for existing blockbusters-is a key part of the relationship strategy, as it means LIXTE Biotechnology Holdings, Inc. doesn't need to be a blockbuster on its own to create value. The company decided to pause further development in Soft Tissue Sarcoma after its Phase 1b trial enrollment finished, choosing to direct resources toward these combination theses where the amplifier role holds the most promise.

Investor relations and presentations at financial and scientific conferences

For a clinical-stage company, investor engagement is about maintaining the runway and demonstrating momentum to satisfy listing requirements. LIXTE Biotechnology Holdings, Inc. has been actively engaging the financial community to support its operations, which included raising capital to regain compliance with Nasdaq listing requirements.

Key investor activities in late 2025 include:

• Presenting at the Spartan Capital Investor Conference 2025 on November 3, 2025, where management conducted one-on-one investor meetings.
• Highlighting Q4 2025 Priorities on October 16, 2025, focusing on clinical execution and strategic business development.
• Completing two financings by August 18, 2025, which included raising an aggregate gross proceeds of approximately $5 million in a private placement, alongside a registered direct offering, totaling $6.5 million raised.
• Scheduling the 2025 Annual Meeting of Stockholders for December 8, 2025.

Staying listed is the difference between playing in the big leagues and getting relegated to obscurity.

Scientific publications to validate the LB-100 mechanism

Scientific validation from peer-reviewed literature is the ultimate form of relationship building with the scientific community and potential future partners. This data directly supports the clinical trial narratives.

Significant validation points reported in 2025 include:

• A new finding published in the journal Nature in August 2025, further validating the promise of LB-100.
• Two breakthrough publications in medical journals, EMBO and Cancer Discovery, reported in March 2025, supporting the clinical trial program.

In the often hype-heavy world of oncology startups, seeing the mechanism reinforced in peer-reviewed literature gave LIXTE Biotechnology Holdings, Inc. a credibility boost money cannot buy.

Lixte Biotechnology Holdings, Inc. (LIXT) - Canvas Business Model: Channels

The channels Lixte Biotechnology Holdings, Inc. (LIXT) uses to reach its key partners and disseminate critical trial data are centered on clinical execution and strategic financial communication as of late 2025.

Direct clinical trial sites (e.g., M.D. Anderson, Netherlands Cancer Institute)

Clinical development relies on established, high-profile cancer centers for running trials on the lead compound, LB-100. These sites are often linked with major pharmaceutical collaborators.

LIXTE Biotechnology Holdings, Inc. is actively using the following primary clinical sites for its proof-of-concept trials:

• M.D. Anderson Cancer Center for the Ovarian Clear Cell Carcinoma (OCCC) trial.
• Northwestern University for the OCCC trial.
• Netherlands Cancer Institute (NKI) for the Colorectal Cancer trial.

Past or supporting trial activities included a Spanish Sarcoma Group (GEIS) trial planned to enroll up to 170 patients for advanced soft tissue sarcomas. LIXTE also initiated a new pre-clinical study with NKI focused on cancer prevention.

Indication	Clinical Site(s)	Collaborating Pharma Partner	Trial Phase/Type
Ovarian Clear Cell Carcinoma (OCCC)	M.D. Anderson Cancer Center, Northwestern University	GSK	Phase 1b/2
Metastatic Colorectal Cancer	Netherlands Cancer Institute (NKI)	F. Hoffmann-La Roche	Clinical Trial

Licensing and co-development agreements with major pharmaceutical companies

Co-development is a primary channel for advancing LB-100, leveraging the resources and established drug platforms of larger entities. These agreements provide essential support, both clinical and financial.

Key partnership details include:

• The collaboration with GSK for the ovarian cancer trial includes provision of dostarlimab and financial support for the study.
• The colorectal trial is supported by F. Hoffmann-La Roche Ltd.
• LIXTE Biotechnology Holdings, Inc. received an Exclusive Patent License Agreement from the NIH on LB-100's potential in enhancing cancer immunotherapies (as of March 2025).
• On November 25, 2025, LIXTE Biotechnology Holdings announced the acquisition of Liora Technologies' Proprietary Proton Therapy Platform for Cancer Treatment.

Scientific and medical conferences for data dissemination

Dissemination of scientific validation and trial progress occurs through peer-reviewed publications and presentations at industry events. Findings validating LB-100 were published in the medical journal Nature in 2025. LIXTE Biotechnology Holdings also presented at the Spartan Capital Investor Conference 2025 on November 3.

Corporate communications and SEC filings for investor outreach

Investor relations utilize formal filings and direct conference participation to communicate financial health and operational milestones. The company reported on its Q4 2025 priorities on October 16, 2025.

Recent financial activities channeled through corporate communications include:

In August 2025, LIXTE Biotechnology Holdings completed two financings, raising aggregate gross proceeds of approximately $6.5 million (a private placement of approximately $5 million and a registered direct offering of approximately $1.5 million). Earlier in February 2025, a financing raised gross proceeds of approximately $1,050,000.

As of August 5, 2025, there were 4,561,363 shares of common stock issued and outstanding. The Investor Phone contact number is (888) 289-5533.

Key SEC filings around late 2025 include the Quarterly Earnings Report for Q3 2025 (filed October 2025) and a Material Event Report (8-K) on November 25, 2025.

Lixte Biotechnology Holdings, Inc. (LIXT) - Canvas Business Model: Customer Segments

You're looking at the core groups Lixte Biotechnology Holdings, Inc. targets with its lead candidate, LB-100, which acts as a PP2A inhibitor (a drug designed to make existing treatments work harder).

The primary customer segments are defined by the specific, high-unmet-need solid tumor indications being pursued in clinical trials, and the strategic partners required to advance those trials.

The patient segment is defined by the specific cancer types where LB-100 is being tested in combination therapies:

• Patients with Ovarian Clear Cell Carcinoma (OCCC).
• Patients with Advanced Soft Tissue Sarcoma (STS).
• Patients with Metastatic Microsatellite-Stable (MSS) Colon Cancer.

The clinical development strategy directly involves specific academic research centers and large pharmaceutical entities, which are key segments for data generation and potential future commercialization.

Customer Segment Detail	Specific Indication/Partner	Relevant 2025 Data/Metric
Specialized Cancer Treatment Centers	The University of Texas MD Anderson Cancer Center and Northwestern University's Robert H. Lurie Comprehensive Cancer Center	Ovarian Clear Cell Carcinoma trial enrollment target: 21 patients.
Large Pharmaceutical Partners (Combination Therapy)	GSK	Providing dostarlimab and full funding for the ovarian program.
Large Pharmaceutical Partners (Combination Therapy)	Roche	Supplying atezolizumab and full funding for the colorectal study.
Clinical Development Focus	LB-100 Phase 1 Trials	Phase 1 tolerability reported with no toxicity concerns.

For the patient segment, the focus is on difficult-to-treat cancers where LB-100 is positioned as a treatment amplifier. For instance, preliminary efficacy data for the OCCC combination trial is anticipated in Q4 2025, and Progression-Free Survival (PFS) and Objective Response Rate (ORR) data for the STS trial is expected in late Q3 2025.

The segment of institutional and accredited investors is critical for funding operations, especially given the company's recent treasury management activities. Lixte Biotechnology Holdings, Inc. made an initial purchase of digital currency totaling $2.6 million in September 2025 to diversify its treasury. Furthermore, the acquisition of Liora Technologies Europe Ltd. involved a consideration package including 10.56 Bitcoin, 300 Ethereum, and $440,000 in cash, alongside a royalty agreement capped at $45 million. The company's stock price was noted at $4.20 on December 3, 2025.

The company is actively pursuing oncology-focused business development, being in advanced negotiations for potential acquisitions of complementary oncology assets to build a multi-asset platform.

Lixte Biotechnology Holdings, Inc. (LIXT) - Canvas Business Model: Cost Structure

You're looking at the cost side of Lixte Biotechnology Holdings, Inc. (LIXT) as they push forward with both their drug pipeline and the new hardware acquisition. For a clinical-stage company, the burn rate is almost entirely driven by science and compliance, so these numbers tell you where the capital is going.

The overall operating expense for the third quarter of 2025 was reported at $1.80 million. This single figure captures the immediate cash outlay for running the business during that period. To be fair, that $1.80 million is the consolidated operating expense, and we can see some of the components from earlier in the year, though the exact Q3 breakdown isn't fully detailed in the same source.

High research and development (R&D) expenses are a given, supporting ongoing clinical trials for compounds like LB-100 in indications such as Ovarian Clear Cell Carcinoma and Metastatic Colon Cancer. Obligations incurred for mandatory scheduled payments under milestone provisions are recognized as charges to R&D costs in the statements of operations. For the three months ended June 30, 2025, R&D costs were $60,648. This is the core investment in future value creation.

General and administrative (G&A) costs cover the executive and corporate overhead necessary to manage the dual-track strategy involving both pharmaceuticals and the new hardware. For the three months ended June 30, 2025, G&A costs totaled $714,161. This covers the corporate infrastructure supporting the company's operations.

The recent strategic move into radiotherapy via the acquisition of Liora Technologies Europe Ltd. introduces a significant associated cost/investment. Over $300 million has been invested to date in developing the proprietary LiGHT System technology itself. Lixte Biotechnology Holdings, Inc. is now focused on operational readiness, including quality, CMC (Chemistry, Manufacturing, and Controls), and regulatory alignment to support the LiGHT System and its integration, though specific dollar amounts for these activities in late 2025 aren't itemized separately in the operating expense line.

Here's a look at the expense components we can quantify from the first half of 2025, which gives you a sense of the scale, even if the Q3 total was higher:

Cost Category	Period	Amount (USD)
Total Operating Expenses	Q3 2025	$1,800,000
Research and Development Costs	Three Months Ended June 30, 2025	$60,648
General and Administrative Costs	Three Months Ended June 30, 2025	$714,161
Total Costs and Expenses	Three Months Ended June 30, 2025	$774,809
Investment in LiGHT System Technology (To Date)	As of November 2025	Over $300 million

The company is defintely shifting its cost base by adding the infrastructure component. You need to track how the integration of the LiGHT System impacts future R&D and G&A, especially as they plan for a recurring revenue model through jointly operated treatment centers. The cost structure is now a blend of pure-play biotech spending and capital asset integration.

• Ongoing clinical execution for LB-100 across prioritized tumor settings.
• Costs associated with the acquisition and integration of the LiGHT proton therapy platform.
• Initiatives in quality, CMC, and regulatory alignment to support study conduct.
• General corporate overhead supporting the expanded, multi-asset oncology platform.

Finance: draft Q4 2025 projected operating expense budget by next Tuesday.

Lixte Biotechnology Holdings, Inc. (LIXT) - Canvas Business Model: Revenue Streams

As a clinical-stage pharmaceutical company, Lixte Biotechnology Holdings, Inc. currently reports no annual drug revenue from commercial sales. The financial results for the third quarter of 2025 indicated a cumulative net loss of USD 3.47 million for the first three quarters of 2025, which is consistent with a pre-revenue business model focused on research and development.

The primary source of operational capital as of late 2025 is external financing, which comes in two main forms: non-dilutive support from pharmaceutical collaborators and proceeds from equity raises.

Non-dilutive funding from pharmaceutical partners is a key component supporting ongoing clinical work for the lead compound, LB-100. This support is structured around specific combination therapy trials:

• GSK is providing dostarlimab-gxly and full funding for the ovarian cancer program trial.
• Roche is supplying atezolizumab and full funding for the colorectal study trial.

The clinical trial combining LB-100 with GSK's dostarlimab-gxly for ovarian clear cell carcinoma is currently expected to be completed by December 31, 2027.

Proceeds from equity financing and private placements provided a significant cash infusion in mid-2025, which was critical for maintaining Nasdaq listing compliance. Lixte Biotechnology Holdings, Inc. regained Nasdaq compliance after raising a total of $6.5 million in funding through a combination of offerings.

Financing Event Component	Announced Date	Expected Gross Proceeds
Private Placement (Initial Closing)	July 01, 2025	$4.0 million
Registered Direct Offering	July 08, 2025	$1.5 million
Private Placement (Contingent Payment)	Announced July 01, 2025	$1.0 million
Total Equity Capital Raised in 2025	Mid-2025	$6.5 million

The initial $5.0 million private placement, priced at the market under Nasdaq rules, involved the sale of Common Stock (or Pre-Funded Warrants), Series B Convertible Preferred Stock, and Common Warrants. The common warrants included an initial exercise price of $1.00 per share.

Potential future revenue streams are entirely contingent upon clinical success and subsequent commercialization or licensing events. These include:

• Potential future milestone payments derived from licensing agreements for LB-100.
• Potential future commercial sales revenue from LB-100, which is a first-in-class inhibitor of protein phosphatase 2A (PP2A).
• Potential future commercial sales revenue from the LiGHT proton therapy system, following Lixte Biotechnology's acquisition of the platform in November 2025.